• In August 2026, Xeris Biopharma Holdings reported that second-quarter revenue rose to US$92.1 million from US$71.54 million a year earlier, while its net loss widened to US$31.1 million and basic loss per share from continuing operations increased to US$0.18.
• For the first half of 2026, revenue grew to US$175.23 million from US$131.66 million year-on-year, but a larger net loss of US$28.87 million and a higher basic loss per share of US$0.17 highlighted the cost of pursuing growth alongside the company’s more tightly defined full-year revenue guidance of US$385 million to US$390 million.
• We’ll now examine how Xeris’s stronger revenue performance but wider quarterly loss could influence the earlier investment narrative around growth and profitability.

AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Xeris Biopharma Holdings Investment Narrative Recap

To own Xeris, you need to believe its focused endocrine portfolio can eventually convert growing sales into durable profitability without overstretching its balance sheet. The latest results show revenue momentum but a sharply wider quarterly loss, which keeps cost control and cash burn as the key near term catalyst and risk. The guidance tightening itself does not materially change that risk balance, but it arguably raises the bar for execution in the coming quarters.

The most relevant update here is Xeris tightening its 2026 revenue guidance to US$385 million to US$390 million. That range sits against a first half revenue base of US$175.23 million and a Q2 net loss of US$31.1 million, so investors may watch closely whether volume growth in Recorlev, Gvoke and Keveyis can support that target without further widening losses or forcing new funding decisions.

Yet behind the stronger sales, investors should be aware that the widening losses and negative equity position could...

Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from $-32.0 million today.

Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some analysts went much further before this update, assuming revenues near US$602 million and earnings of about US$164 million, which paints a far more optimistic picture than a risk view focused on rising costs, and reminds you that these new results could shift both the bullish and cautious narratives in different directions.

Explore 3 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.